Literature DB >> 7903033

Molecular analysis of the pathogenicity of Streptococcus pneumoniae: the role of pneumococcal proteins.

J C Paton1, P W Andrew, G J Boulnois, T J Mitchell.   

Abstract

For many years the virulence of Streptococcus pneumoniae has largely been attributed to its antiphagocytic polysaccharide capsule. Recent evidence, however, indicates that certain pneumococcal proteins play an important part in the pathogenesis of disease, either as mediators of inflammation or by directly attacking host tissues. Pneumococci carrying defined mutations in the genes encoding any one of at least three pneumococcal proteins (the toxin pneumolysin, the major pneumococcal autolysin, and pneumococcal surface protein A) have significantly reduced virulence. Pneumococcal hydrolytic enzymes, such as neuraminidase, hyaluronidase, and IgA1 protease may also contribute to colonization and/or invasion of the host. Several of these proteins (or their detoxified derivatives) are protective immunogens in animal models and therefore warrant consideration for inclusion in human antipneumococcal vaccine formulations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903033     DOI: 10.1146/annurev.mi.47.100193.000513

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  93 in total

Review 1.  Streptococcus pneumoniae.

Authors:  J R Catterall
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin.

Authors:  P Balachandran; S K Hollingshead; J C Paton; D E Briles
Journal:  J Bacteriol       Date:  2001-05       Impact factor: 3.490

3.  Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis.

Authors:  Johann S Braun; Jack E Sublett; Dorette Freyer; Tim J Mitchell; John L Cleveland; Elaine I Tuomanen; Joerg R Weber
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

4.  Sensitivities of human monocytes and epithelial cells to pneumolysin are different.

Authors:  Robert A Hirst; Hasan Yesilkaya; Edwin Clitheroe; Andrew Rutman; Nichola Dufty; Timothy J Mitchell; Christopher O'Callaghan; Peter W Andrew
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

5.  RegR, a global LacI/GalR family regulator, modulates virulence and competence in Streptococcus pneumoniae.

Authors:  Sabine Chapuy-Regaud; A David Ogunniyi; Nicole Diallo; Yvette Huet; Jean-François Desnottes; James C Paton; Sonia Escaich; Marie-Claude Trombe
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

6.  Contribution of serotype and genetic background to virulence of serotype 3 and serogroup 11 pneumococcal isolates.

Authors:  Lauren J McAllister; Abiodun D Ogunniyi; Uwe H Stroeher; Amanda J Leach; James C Paton
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

7.  Purification and polar localization of pneumococcal LytB, a putative endo-beta-N-acetylglucosaminidase: the chain-dispersing murein hydrolase.

Authors:  Blanca De Las Rivas; José L García; Rubens López; Pedro García
Journal:  J Bacteriol       Date:  2002-09       Impact factor: 3.490

8.  Sialic acid-mediated gene expression in Streptococcus pneumoniae and role of NanR as a transcriptional activator of the nan gene cluster.

Authors:  Muhammad Afzal; Sulman Shafeeq; Hifza Ahmed; Oscar P Kuipers
Journal:  Appl Environ Microbiol       Date:  2015-02-27       Impact factor: 4.792

9.  Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.

Authors:  J E Alexander; R A Lock; C C Peeters; J T Poolman; P W Andrew; T J Mitchell; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

10.  Large-scale identification of virulence genes from Streptococcus pneumoniae.

Authors:  A Polissi; A Pontiggia; G Feger; M Altieri; H Mottl; L Ferrari; D Simon
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.